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A B S T R A C T
Translocator protein (18 kDa) (TSPO) is a mitochondrial protein expressed by reactive microglia and astrocytes
at the site of neuronal injury. Although TSPO function has not been fully determined, synthetic TSPO ligands
have beneﬁcial eﬀects on diﬀerent pathologies of the central nervous system, including the retina. Here, we
studied the pattern of Tspo expression in the aging human retina and in two mouse models of retinal degen-
eration. Using a newly generated Tspo-KO mouse, we investigated the impact of the lack of TSPO on retinal
morphology, function and susceptibility to degeneration. We show that TSPO was expressed in both human and
mouse retina and retinal pigment epithelium (RPE). Tspo was induced in the mouse retina upon degeneration,
but constitutively expressed in the RPE. Similarly, TSPO expression levels in healthy human retina and RPE were
not diﬀerentially regulated during aging. Tspo-KO mice had normal retinal morphology and function up to 48
weeks of age. Photoreceptor loss caused either by exposure to excessive light levels or by a mutation in the
phosphodiesterase 6b gene was not aﬀected by the absence of Tspo. The reactivity states of retinal mononuclear
phagocytes following light-damage were comparable in Tspo-KO and control mice. Our data suggest that lack of
endogenous TSPO does not directly inﬂuence the magnitude of photoreceptor degeneration or microglia acti-
vation in these two models of retinal degeneration. We therefore hypothesize that the interaction of TSPO with
its ligands may be required to modulate disease progression.
1. Introduction
Translocator protein (18 kDa) (TSPO) was identiﬁed in 1977
(Braestrup et al., 1977) and initially named peripheral benzodiazepine
receptor. TSPO is a 169-amino acid protein located in the outer mi-
tochondrial membrane (Anholt et al., 1985) (reviewed in(Rupprecht
et al., 2010)) and encoded by a nuclear gene consisting of four exons,
with exon two containing the START-codon (Sileikyte et al., 2014).
TSPO forms a channel with ﬁve α-helical transmembrane domains and
contains a cholesterol-recognition amino acid consensus (CRAC) se-
quence at its C-terminal end that folds toward the lipid membrane
(Jaremko et al., 2014). TSPO has been connected to the mitochondrial
transition pore regulation (Chelli et al., 2001) (Azarashvili et al., 2015),
steroid synthesis (reviewed in (Rupprecht et al., 2010; Selvaraj et al.,
2015)), Ca2+ homeostasis (Gatliﬀ et al., 2017), reactive oxygen species
production (Gatliﬀ et al., 2014) and energy metabolism (Liu et al.,
2017; Tu et al., 2016). However, none of these functions has been
broadly conﬁrmed and the molecular and physiological role of TSPO
remains elusive.
TSPO was ﬁrst identiﬁed as a peripheral binding site for benzodia-
zepines, such as diazepam. Since benzodiazepines are used to treat
psychiatric disorders, TSPO ligands were investigated as possible
therapeutics. Indeed, TSPO ligands exerted beneﬁcial outcomes for
anxiety disorders in animal models and human patients (reviewed in
(Nothdurfter et al., 2012; Rupprecht et al., 2010; Rupprecht et al.,
2009). It was suggested that this eﬀect may be related to the ability of
the ligands to increase levels of (neuro)steroids, such as allopregnano-
lone, and therefore modulate activity of GABAA (Bitran et al., 2000;
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Nothdurfter et al., 2012; Rupprecht et al., 2009). High levels of TSPO in
steroidogenic tissues such as gonads, adrenals and brain (Papadopoulos
et al., 2006), its localization in the outer mitochondrial membrane
(Anholt et al., 1985), its channel-like structure and the presence of a
CRAC on its cytosolic terminal (Jaremko et al., 2014) made TSPO an
appealing candidate for being involved in cholesterol traﬃcking. Thus,
TSPO was proposed to transport cholesterol from the cytosol into the
mitochondrial matrix, the rate limiting step in steroidogenesis
(Papadopoulos et al., 2006). However, recent studies have failed to
detect any deﬁcit in steroid synthesis following genetic ablation of Tspo,
reopening the debate about the role of Tspo in steroidogenesis
(Morohaku et al., 2014; Sileikyte et al., 2014; Tu et al., 2014, 2016).
Interestingly, transcriptomic analysis of adrenal glands from Tspo-KO
mice revealed no eﬀect on steroidogenic pathways but detected dif-
ferential regulation of genes involved in the immune response (Tu et al.,
2014). Indeed, it is generally accepted that TSPO is regulated in various
immune cell populations. Following brain injury for example, TSPO
levels increase in primary and secondary injury sites due to activation
of microglia (reviewed in (Bennett et al., 2016)) and astrocytes
(Cosenza-Nashat et al., 2009; Guilarte, 2019). Its regulation in brain
microglia and astrocytes during pathologies and its speciﬁc interaction
with several radioligands makes TSPO an attractive tool to diagnose
and follow neuroinﬂammation by positron-emission tomography (PET;
reviewed in (Best et al., 2019)).
Furthermore, application of TSPO ligands showed positive eﬀects in
mouse models for neuropathies, such as peripheral nerve lesions,
Parkinson's disease, Alzheimer disease and multiple sclerosis (Gong
et al., 2019; Guilarte, 2019; Leva et al., 2017) reviewed in (Best et al.,
2019). Similarly, recent data also support a neuroprotective potential of
systemically applied TSPO ligands for retinal structures (Leva et al.,
2017; Scholz et al., 2015). Scholz et al. demonstrated that XBD173, a
synthetic TSPO ligand, dampened microglia activation and preserved
the retinal structure in Balb/c mice following exposure to toxic levels of
light (Scholz et al., 2015).
In view of the increasing diagnostic and therapeutic relevance of
TSPO ligands for brain and retinal pathologies, it is important to better
characterize TSPO function and regulation. Although TSPO is expressed
in the mouse neural retina and retinal pigment epithelium (RPE) and
TSPO ligands may inﬂuence retinal homeostasis in pathogenic situa-
tions (Karlstetter et al., 2014; Scholz et al., 2015), not much is known
about its dynamics and potential function in ocular tissues. Thus, we
studied TSPO expression in diﬀerent mouse models of retinal degen-
eration and in human retinas collected from post-mortem donors. We
also generated a Tspo–/– mouse (Tspo-KO), followed its retinal devel-
opment and function, and analysed the susceptibility of its retina to
stress-induced degeneration.
2. Material and methods
2.1. Mice and generation of Tspo knockouts
Mouse colonies were maintained at the Laboratory Animal Service
Center (LASC) of the University of Zurich under a cycle of 14 h light and
10 h darkness with free access to food and water. Mice were euthanized
by suﬀocation with CO2 followed by cervical dislocation. All
experiments were approved by the veterinary authorities of Canton
Zurich, Switzerland and adhered to the ARVO Statement for the Use of
Animals in Ophthalmic and Vision Research.
Tspo-KO mice were generated on a mixed background by crossing
Tspoﬂox/ﬂox (Sileikyte et al., 2014) mice with BEST1-Cre mice (Iacovelli
et al., 2011). To introduce the Rpe65450Leu variant that increases light-
damage susceptibility (Wenzel et al., 2001), Tspoﬂox/ﬂox; BEST1-Cre
mice were backcrossed to Balb/c mice for one generation, followed by
the intercross of F1 pups. To obtain homogeneous fur pigmentation
within our mouse colony, we selected mice homozygous for tyr-
osinaseCys95 (Alexeev and Yoon, 1998). A naturally occurring single
nucleotide polymorphism (e.g. in 129/S6 mice) in Tspo causes the ex-
change of proline with alanine at amino acid position 168. Since this
renders TSPO not detectable with our anti-TSPO antibody (CAT:
ab109497, AbCam, Cambridge, UK), mice homozygous for the
Tspo168Pro variant were selected for further breeding. BEST1-Cre is oc-
casionally active in germ line cells resulting in oﬀspring carrying
monoallelic excision of the ﬂoxed gene (Iacovelli et al., 2011). Mice
bearing a monoallelic excision of Tspo were intercrossed to generate bi-
allelic whole-body Tspo-KOs. Tspoﬂox/ﬂox mice were used as controls
(CTRL).
Tspo-KO mice were also crossed with rd10 mice that carry a muta-
tion in phosphodiesterase 6b (Pd6brd10) leading to photoreceptor loss
(reviewed in (Chang et al., 2002)). Brieﬂy, Tspo-KO mice were bred
with Pd6brd10 mice to generate Tspo–/–;rd10/rd10 (Tspo-KO;rd10) mice
in the second generation. rd10/rd10 (rd10) were used as controls. Mice
were genotyped by conventional PCR on genomic DNA isolated from
ear biopsies using speciﬁc primer pairs listed in Table 1.
2.2. Light damage
Eyes of dark-adapted mice were dilated under dim-red light with 1%
cyclogyl (Alcon Pharmaceutical, Cham, Switzerland) and 5% pheny-
lephrine (Ciba Vision, Niederwangen, Switzerland). Mice were then
single caged in aluminium-coated cages and exposed to 10′000 lux of
white light for 2 h. Following light exposure, mice were returned to
their normal housing cages and kept in darkness overnight before re-
turning them to a 12 h:12 h light-dark cycle. Tissues were collected at
12 h, and at 4 and 14 days post-exposure. Dark control mice (DC) were
treated in parallel but kept in darkness.
2.3. Electroretinography (ERG)
Mice were dark-adapted over night. Prior to ERG recording, pupils
were dilated as described above. Mice were anesthetized by a sub-
cutaneous injection of a mixture of Ketamine (85 mg/kg, Parke-Davis,
Berlin, Germany) and Rompun (Xylazine, 4 mg/kg, Bayer AG,
Leverkusen, Germany) and placed on a heated pad. Golden ring elec-
trodes were placed onto each cornea. Mice were exposed to light ﬂashes
ranging from −50 dB (0.000025 cd*s/m2) to 15 dB (79 cd*s/m2) for
scotopic and from −10 dB (25 cd*s/m2) to 25 dB (790 cd*s/m2) for
photopic ERG. Mice were light-adapted for 5min prior to photopic
ERG. Light-evoked retinal responses were recorded with an LKC UTAS
Bigshot unit (LKC Technologies, Inc. Gaithersburg, MD, USA). For each
light intensity, 10 recordings were averaged.
Table 1
Genotyping primers.
Gene Forward 5′-3′ Reverse 5′-3′
Tspo ﬂox/ﬂox (Šileikytė et al., 2014) GGATTACCACACCCAACCAG TAGGAGTGCAAAGCCAGTCA
Tspo excision GCTGGAATGACAGGTGGAT CCTCTGTTCTCAGCTTCAGT
Tspo168Pro CCACCGTGCTCAACTACTA GCCCAATGGTCATAAAAG
Rpe65450Leu (Grimm et al., 2004) CACTGTGGTCTCTGCTATCTTC GGTGCAGTTCCACTTCAGTT
Tyr c/c (Alexeev and Yoon, 1998) AAGAATGCTGCCCACCATG GACATAGACTGAGCTGATAGTATGTT
BEST1-Cre (Iacovelli et al., 2011) ATGCCCAAGAAGAAGAGGAAGGTGTCC GCCCAATGGTCATAAAAG
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2.4. Optical coherence tomography (OCT)
Dilation of pupils and anaesthesia were performed as described
above. A drop of 2% Methocel (OmniVision AG, Neuhausen,
Switzerland) was applied to each eye to keep the cornea moist. Mice
were placed on a heated holder and fundus images and OCT scans were
acquired using the Micron IV system (Phoenix Research Labs,
Pleasanton, CA, USA).
2.5. Tissue dissection
Eyes of euthanized mice were held in place using a pair of forceps.
The eyeballs were opened by slitting the cornea using a sharp scalpel.
Lens and vitreous were removed through this slit, the neural retina
isolated and quickly frozen in liquid nitrogen. The remaining eyecup
(EC, representative for RPE/choroid) was cut from the eye socket using
scissors and frozen in liquid nitrogen.
2.6. Retinal ﬂat mounts
Preparation of retinal ﬂat mounts was as described recently
(Caprara et al., 2011). Brieﬂy, left and right eyes were enucleated and
ﬁxed for 10min in 4% PFA (in 0.1M phosphate buﬀer). Thereafter, the
cornea was punched and eyes were post-ﬁxed for additional 20min in
4% PFA. Eyeballs were opened, cut into a cloverleaf shape and ﬂattened
with brushes. The lens was carefully removed and the retina was gently
pulled away from the eyecup. Isolated retinas were post-ﬁxed for 1 h in
4% PFA and incubated for 1 h in blocking solution (3% normal goat
serum (Sigma-Aldrich, St. Louis, MO, USA), 0.3% Triton X-100 (Sigma-
Aldrich, Buchs SG, Switzerland)). Flat mounts were stained following
the standard immunoﬂuorescence protocol (see 2.9 Immuno-
ﬂuorescence) and mounted on glass slides.
2.7. Human retina and RPE samples
Collection of eye bulbs from post-mortem donors at the University
Hospital of Zurich was approved by the ethics committee of Canton
Zurich, Switzerland (BASEC-Nr: PB_2017-00550), and adhered to the
tenets of the Declaration of Helsinki. Donor age ranged from 17 to 90
years. Only eyes from donors without diagnosed eye disease were in-
cluded in the study. Age, gender and known diseases of donors are
listed in Table 2. After removal of the cornea, eyeballs were immerged
in PBS and cut into a clover-leaf structure. Lens and vitreous were
carefully removed and nasal mid-peripheral and central retina dis-
sected. Retina and RPE were isolated separately, snap frozen and stored
in liquid nitrogen until use. RNA was isolated using the RNeasy kit
(Qiagen, Hilden, Germany) following the manufacturer's instruction.
cDNA synthesis was as described below.
2.8. Western blotting
Proteins were isolated from whole neural retinas, ECs or small
fragments of kidney and liver. Tissues were homogenised in 200 μl of
Tris-HCL (100mM, pH 8.0) by sonication and centrifuged for 3min at
1′000 rcf. Protein concentration was determined in the supernatant
using the Bradford assay reagent (BioRad, Cressier, Switzerland). 30 μg
of proteins were loaded onto an SDS-PAGE, separated according to their
size and transferred to a nitrocellulose membrane. The membrane was
blocked using 5% non-fat milk as blocking agent (BioRad, Cressier,
Switzerland) and incubated over night at 4 °C with anti-TSPO (1:2′500,
ab109497, AbCam, Cambridge, UK) and anti-ACTB (1:1′000, A5441,
Sigma-Aldrich, Buchs SG, Switzerland) antibodies diluted in 5%
blocking milk. Thereafter, membranes were incubated with the ap-
propriate HRP-conjugated secondary antibody (anti-mouse, 1:10′000,
sc-2031, Santa Cruz, Nunningen, Switzerland; anti-rabbit 1:10′000, P-
5282, Sigma-Aldrich, Buchs SG, Switzerland). ECL-chemoluminescence
(PerkinElmer, Waltham, MA, USA) was visualized using an X-Ray ﬁlm.
2.9. Immunoﬂuorescence
Following euthanasia, the right eye was marked nasally and en-
ucleated. Eyes were ﬁxed in 4% PFA (in 0.1M phosphate buﬀer) for 2 h.
Then the cornea was cut and eyes were returned to PFA for over night
incubation at 4 °C. After removal of the lens, eyes were post-ﬁxed for
2 h in 4% PFA at 4 °C, immerged in 30% sucrose for 2 h and embedded
in aluminium molds ﬁlled with tissue freezing medium (O.C.T., Leica
Biosystems Nussloch GmbH, Nussloch, Germany). Blocks were stored at
−80 °C until sectioning. 12 μm thick cryosections containing the optic
nerve head were blocked for 1 h at room temperature in blocking so-
lution (3% normal goat serum (Sigma-Aldrich, St. Louis, MO, USA),
0.3% Triton X-100 (Sigma-Aldrich, Buchs SG, Switzerland)). Then,
cryosections were incubated with the primary antibody (anti-TSPO,
1:500, ab109497, AbCam, Cambridge, UK; anti-IBA-1, 1:500,
019–19741, Wako Chemicals GmbH, Neuss, Germany) over night at
4 °C. Following three wash steps with phosphate-buﬀered saline, cryo-
sections were incubated with secondary antibodies (Cy3-labelled anti-
rabbit, 111-165-003, Jackson ImmunoResearch Laboratories,
Westgrove, PA, USA) for 1 h at room temperature and nuclei were
counterstained with DAPI (4′,6-Diamidine-2′-phenylindole dihy-
drochloride, Roche, Basel, Switzerland). Fluorescent signals were ana-
lysed by ﬂuorescence microscopy (Axioplan 2, Zeiss, Feldbach,
Switzerland).
2.10. Morphology
Following euthanasia, the cornea of the left eye was marked dor-
sally. Eyes were enucleated, ﬁxed over night at 4 °C in 2.5% glutar-
aldehyde/0.1 M cacodylate buﬀer and cut through the optic nerve head
into a dorsal and ventral part. Both dorsal and ventral retina were
washed in cacodylate buﬀer (0.1M, pH 7.2), ﬁxed for 1 h at room
temperature in 1% osmium tetroxide (in cacodylate buﬀer). Following
dehydration, retinas were embedded in Epon, cut into 0.5 μm thick
sections and counterstained with toluidine blue. Ventral retinas were
analysed by light microscopy with an Axioplan 2 microscope (Zeiss).
2.11. Nuclei and quantiﬁcation of IBA1-positive microglia cells
Images of retinal morphologies were merged to generate panoramas
Table 2
Details about human donors.
Human eye Age Gender Known disease
6 57 M –
7 77 M –
8 90 M –
9 76 M Adenocarcinoma
10 65 M Diabetes Type 2
11 58 M Colitis ulcerosa
12 64 M –
13 80 F Coronary disease
14 58 F Depression
16 74 M –
17 78 M Coronary disease
18 83 F –
19 17 M –
21 83 F Hypertension
22 46 M Leukemia
23 82 M –
24 83 F Epilepsy
25 31 M –
26 53 M Hypertension
27 34 F Alcohol addition
28 59 F Diabetes Type
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using Adobe Photoshop CS6 (Adobe Systems Inc., San Jose, CA, USA).
Nuclei counts were performed by placing 75 μm×37.5 μm squares
(2′812.5 μm2) on the ONL at 200, 400, 800, 1′200 and 1′600 μm dis-
tance on either side of the optic nerve head. The short edge of the
square was placed parallel to the RPE. Nuclei in this square were
manually counted using ImageJ (Schneider et al., 2012).
IBA1-positive cells were quantiﬁed on retinal ﬂat mounts using
ImageJ (Schneider et al., 2012). For each ﬂat mount, a rectangular area
of 450 μm2×320 μm2 was selected in each of the four arms of the
cloverleaf-shaped retina in an equal distance from the optic nerve.
IBA1-positive cells were counted in these areas discarding microglias/
macrophages crossing the area border. The focus plane was on the GCL
for dark control mice since resident microglia are found in this layer of
non-stressed retinas. The focus plane was shifted to the ONL in light
exposed retinas as IBA1-positive cells move toward the ONL upon
photoreceptor damage.
2.12. RNA isolation, cDNA synthesis and real-time PCR
Retina and ECs were homogenised by passing the tissue 10 times
through a 21G needle. EC homogenates were centrifuged for 3min at
3′000 rcf to pellet the sclera and RNA puriﬁcation was performed on the
supernatant. Total RNA was isolated using the MN Nucleo Spin RNA
isolation Kit (Macherey-Nagel, Oensingen, Switzerland). cDNA was
synthetized using oligo-dT primers and M-MLV reverse transcriptase
(Promega, Dübendorf, Switzerland). 10 ng of cDNA were used to de-
termine relative transcript levels of speciﬁc genes by real-time PCR
using an ABI QuantStudio3 device (Thermo Fisher Scientiﬁc, Waltham,
MA, USA), the PowerUp SYBR Green master mix (Thermo Fisher
Scientiﬁc) and speciﬁc primer pairs (Table 3). Transcript levels were
normalized to Actb and relative expression calculated using the ΔΔCt
method using the Thermo Fisher Cloud software. LightCycler480
(Roche Diagnostics, Rotkreuz, Switzerland) with SybrGreen I master
mix (Roche Diagnostics) was used to measure Tspo mRNA levels in the
retina and eyecup of B6 and rd10 mice (Fig. 2A). Normalization of
transcript levels was performed with the LightCycler480 software
(Roche Diagnostics, Rotkreuz, Switzerland).
3. Results
3.1. Tspo is highly expressed in the mouse RPE
We have recently shown that TSPO is expressed not only in the
mouse retina but also in the RPE (Scholz et al., 2015; Storti et al.,
2017). Using semi-quantitative real-time PCR we now estimated its
relative expression levels in both tissues. Since a direct comparison of
mRNA levels in diﬀerent tissues is not possible by this method due to
potentially diﬀerent expression levels of the reference gene, we de-
termined cycle threshold (Ct) values of Tspo and Actb in 10 ng cDNA
from the mouse retina and eyecup (EC). Whereas mean Ct values of Actb
were not diﬀerent between ECs (Ct: 18.63) and retina (Ct: 19.26), Ct
values of Tspo were signiﬁcantly lower in the EC (Fig. 1A), suggesting
several-fold higher expression levels of Tspo mRNA in EC. Immuno-
ﬂuorescence staining on mouse cryosections conﬁrmed the high ex-
pression level of TSPO in the RPE whereas signals were weak in the
retina and conﬁned to the inner layers, probably coming from labelled
blood vessels (Wang et al., 2014) and astrocytes (Cosenza-Nashat et al.,
2009) cells (Fig. 1B).
3.2. Retinal degeneration upregulates Tspo in the retina but not EC
Despite the controversial results about TSPO function, there is a
general consensus that expression of TSPO is upregulated in reactive
microglia in the CNS including the retina (Karlstetter et al., 2014;
Scholz et al., 2015) reviewed in (Bennett et al., 2016; Guilarte, 2019).
To determine whether expression of Tspo is also regulated in ECs upon
retinal degeneration, we measured Tspo transcript levels in retinas and
ECs of two degenerative mouse models that are characterized by pri-
mary defects in rods (rd10; reviewed in(Chang et al., 2002)) or RPE
cells (RPEΔAbca1;Abcg1; (Storti et al., 2019);). Whereas retinas of rd10
mice start to degenerate around post-natal day (PND) 15 (Samardzija
et al., 2012), RPE-speciﬁc conditional Abca1 and Abcg1 double knock-
outs (RPEΔAbca1;Abcg1 BEST1-Cre+) show strong retinal degeneration
and RPE defects around 24 weeks of age (Storti et al., 2019). Both
models had increased retinal expression levels of Tspo concomitantly
with degeneration of the retina and microglia activation (Fig. 2A and B;
upper panels). Expression of Tspo in the EC, however, was not induced
by the degenerative processes in the retina and/or in the RPE (Fig. 2A
and B; lower panels), suggesting that Tspo expression is regulated in the
retina, but constitutive in the EC.
TSPO has been shown to be expressed in the human retina as well
(Karlstetter et al., 2014; Storti et al., 2019), but to our knowledge its in
vivo expression in the human RPE has not been described. We therefore
determined TSPO mRNA levels in the peripheral and central retina and
RPE of 21 human donor eyes that were not diagnosed with retinal
pathology. As in the mouse eye, TSPO was strongly expressed in both
human tissues. Although not as pronounced as in the mouse (Fig. 1A),
the signiﬁcantly lower Ct values indicated stronger expression of TSPO
in the RPE of the human eye (Fig. 2C). When expression levels in the
central and the peripheral retina were blotted separately against donor
age (from 17 to 90 years), we observed steady levels of TSPO for both
the central and peripheral retina and RPE (Fig. 2C) suggesting that
TSPO expression is not diﬀerentially regulated during normal aging.
Interestingly however, the peripheral RPE expressed TSPO at higher
levels than the central RPE (Fig. 2C) whereas expression levels in the
central and peripheral retina were not diﬀerent (data not shown). The













Mrc1 GGTGAACGGAATGATTGTGTA G CGGTGACCACTCCTGCTG
Cas1 GGCAGGAATTCTGGAGCTTCAA GTCAGTCCTGGAAATGTGCC
TSPO (human) TCTGGGGCACGCTCTACT CAGCAGGAGATCCACCAAGG
ACTB (human) CCTGGCACCCAGCACAAT GGGCCGGACTCGTCATAC
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Fig. 1. Expression of Tspo in the mouse retina and eyecup. A) Tspo and Actb transcript levels in the retina (circles) and EC (triangles) of wild type mice were determined
by real-time PCR in 10 ng of cDNA and shown as Ct values. B) Immunoﬂuorescence staining using anti-TSPO antibody (orange, left panel) or secondary antibody only
(sec. AB, right panel). Blue: DAPI. Arrows: blood vessels. Arrowhead: positive TSPO signal in the ganglion cell layer (GCL). RPE: retinal pigment epithelium, PS:
photoreceptor segments, ONL: outer nuclear layer, INL: inner nuclear layer. N = 3. Statistics: Student t-test. ns: p > 0.05, ***: p ≤ 0.001. Scale bar: 50 μm.
Fig. 2. Ocular expression of Tspo in mouse models of retinal degeneration and human donor eyes. A) Relative Tspo transcript levels in the retina (upper panel) and EC
(lower panel) of B6 wild type (B6, orange) and rd10 (green) mice during post-natal development and ageing. Tspo transcript levels are expressed relatively to B6 mice
at PND1, which were set to 1 for both retina and EC. B) Relative Tspo transcript levels in the retina (upper panel) and EC (lower panel) of RPEΔAbca1;Abcg1 (BEST- Cre
+, magenta) and control (BEST1- Cre-, black) mice at 8, 16 and 24 weeks of age. Tspo transcript levels are expressed relatively to BEST1cre-mice at week 8, which
were set to 1 for both retina and EC. N≥ 3. Shown are individual values and means ± SD. C) Left panels: TSPO and ACTB Ct values were determined in 10 ng of
cDNA from central and peripheral retinas and RPE (each dot represents one sample, values for central and peripheral retinas are blotted in the same graph). Shown
are individual values and means ± SD. Right panels: relative TSPO transcript levels in the central and peripheral retina and RPE of donor eyes expressed as a
function of age and comparison of TSPO expression levels between central and peripheral human RPE. Cent: central RPE; Per: peripheral RPE. N=21 donor eyes.
Statistics: A, B: t-test corrected for multiple comparisons with the Holm-Sidak method; C: Students t-test and linear regression analysis. *p ≤ 0.05, **p ≤ 0.01,
***p ≤ 0.001.
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3.3. Validation of the Tspo-KO mouse
To study the consequences of Tspo loss in the mouse eye, we gen-
erated a full Tspo-KO mouse by crossing Tspoﬂox/ﬂox mice (Sileikyte
et al., 2014) with BEST1-Cre mice that occasionally activate CRE in the
germline (Iacovelli et al., 2011) (see section Material and Methods for
more details). The resulting Tspo-KO mice lacked the second exon (that
contains the AUG start codon) and third exon of the Tspo gene. Im-
munoﬂuorescence staining of retinal cryosections, real-time PCR of
cDNA derived from ECs and Western blots of EC, liver and kidney
conﬁrmed the absence of TSPO in KO mice (Fig. 3A–C).
3.4. Tspo-KO mice have normal retinal morphology and function
To unveil possible ocular phenotypes arising from the absence of
TSPO protein we followed Tspo-KO and control (CTRL) mice until 48
weeks of age (Fig. 4). Fundus photography and optical coherence to-
mography (OCT) at 24 and 48 weeks of age revealed normal fundus
appearance and retina layering for both mouse strains (Fig. 4A). Be-
cause fundus photography and OCT scans are not suitable to detect
minor changes in retinal morphologies, we analysed eyes from CTRL
and Tspo-KO mice by light microscopy. Analysis conﬁrmed the normal
morphology of RPE (Fig. 4B, upper panels) and retina (Fig. 4B, lower
panels) in Tspo-KOmice at 24 and 48 weeks of age. This is supported by
similar numbers of photoreceptor nuclei counted at deﬁned positions
along the naso-temporal axis in 24- and 48-week-old CTRL and Tspo-KO
mice (Fig. 4C).
Because a normal retinal structure may not necessarily translate into
normal function, we determined the electroretinographic (ERG) re-
sponse to light stimuli in CTRL and Tspo-KO mice (Fig. 4D and E).
Overlays of scotopic (Fig. 4D) and photopic (Fig. 4E) ERG traces re-
corded from dark- and light-adapted mice, respectively, suggested
normal scotopic and photopic retinal function of 48-week-old Tspo-KO
mice, an interpretation further supported by similar a- and b-wave
amplitudes in CTRL and Tspo-KO mice at 24 and 48 weeks of age
(Fig. 4D and E; right graphs). We therefore concluded that the systemic
absence of TSPO did not aﬀect retinal structures or function during
development and ageing.
3.5. Tspo-KO and CTRL mice are equally susceptible to retinal degeneration
The fact that TSPO is expressed in activated microglia (reviewed in
(Bennett et al., 2016)) and astrocytes (Cosenza-Nashat et al., 2009;
Guilarte, 2019) upon neuronal damage and inﬂammation suggests that
TSPO is a stress-related protein. Hence, lack of a phenotype in Tspo-KO
mice during normal development and ageing may not be surprising. To
investigate the consequences of the absence of TSPO for the stressed
retina, we induced photoreceptor degeneration by exposing mice to
toxic levels of white light. A set of mice kept in darkness served as dark
controls (DC). We collected ocular tissues of DCs and light-damaged
(LD) mice at 4 and 14 days post-illumination to analyse retinal mor-
phology and count photoreceptor nuclei (Fig. 5A–D). As expected,
retinal morphologies of DC mice were intact and normal for both
genotypes (Fig. 5B). Following light exposure we observed a time-de-
pendent thinning of the ONL that was similarly extensive in CTRL and
Tspo-KO mice (Fig. 5C and D). To quantify loss of photoreceptors we
counted nuclei in the ONL along the naso-temporal axis (see Material
and Methods for more details). The number of photoreceptor nuclei
dropped at 4 days post-illumination and was further reduced at 14 days
after exposure (Fig. 5A). Importantly, the numbers of photoreceptor
nuclei were comparable between CTRL and Tspo-KO mice at matching
time points suggesting that TSPO did not modulate retinal susceptibility
to light-induced photoreceptor degeneration. In addition, lack of TSPO
did not inﬂuence degeneration in the rd10 mouse (Fig. 5E and F), even
though Tspo expression was strongly upregulated during the degen-
eration phase in rd10 retinas (Fig. 2). This indicates that TSPO is not
essential for disease progression both in induced and inherited models
of retinal degeneration.
It is known that light-induced retinal degeneration has an in-
ﬂammatory component characterized by the transient migration of
activated microglia and macrophages into the subretinal space (Joly
et al., 2009; Natoli et al., 2016; Ng and Streilein, 2001; Santos et al.,
2010; Zhang et al., 2005). Light microscopy of retinal morphologies at 4
days after light exposure suggested the subretinal presence of phago-
cytic cells both in CTRL and Tspo-KO mice (yellow arrowheads in
Fig. 5C), indicating that absence of TSPO did not prevent recruitment of
such cells to the site of damage.
3.6. Tspo-KO and CTRL mice show comparable mononuclear phagocyte
dynamics during light-induced photoreceptor degeneration
TSPO is expressed in activated microglia (reviewed in (Bennett
et al., 2016)) and TSPO ligands can modulate microglia activity in brain
and retinal pathologies by shifting microglia toward an anti-in-
ﬂammatory and immunoregulatory state (Scholz et al., 2015). This may
lead to a better tissue preservation. However, mechanisms behind li-
gand-induced modulation of microglia activity and tissue protection are
unclear, and data in Fig. 5C suggested that retinal microglia can be
activated and/or monocytes recruited also in absence of TSPO. This was
conﬁrmed by IBA-1 staining on retinal sections at 4 and 14 days post-
illumination (Fig. 6A). Whereas IBA-1 positive cells were found in the
inner retina of DC mice, the staining highlighted activated microglia
and macrophages in the outer retina of both CTRL and Tspo-KO mice at
4 days after light exposure. Some IBA-1 positive cells were still present
in the subretinal space of both mice even at 14 days post-exposure.
Importantly, we could not identify obvious diﬀerences between CTRL
and Tspo-KOmice with respect to the location of IBA-1 positive immune
cells (Fig. 6A). Staining for TSPO conﬁrmed the knockout and de-
monstrated the presence of TSPO-positive cells in the outer retina of
CTRL mice after light exposure (Fig. 6B). These cells were likely the
Fig. 3. Validation of Tspo-KO mice. A) Tspo transcript levels in ECs of CTRL and Tspo-KO mice were normalized to Actb and shown as individual values and
means ± SD. nd: not detected. B) Detection of TSPO protein levels by Western blotting in EC, liver (L) and kidney (K) lysates of CTRL and Tspo-KO mice. ACTB was
used as loading control. C) Immunoﬂuorescence staining of control (CTRL) and Tspo-KO (KO) mice for TSPO (orange). Abbreviations as in Fig. 1. Scale bar: 50 μm.
N=3.
K. Klee, et al. Experimental Eye Research 188 (2019) 107816
6
inﬂammatory cells detected in Fig. 6A as activated microglia were
shown to express TSPO (Karlstetter et al., 2014).
To quantify the number of microglia cells in Tspo-KO and control
mice, we stained retinal ﬂat mounts with IBA1 (Fig. 6C) and counted
cells in the GCL of dark controls and the ONL of light-exposed mice.
Data indicate that lack of TSPO did not alter the number of ramiﬁed
microglia in the GCL of non-exposed mice or the number of activated
microglia of an amoeboid shape in the ONL at 4 days after light ex-
posure (Fig. 6D). No microglia were detected in the ONL of dark control
mice (not shown).
Because immunoﬂuorescence stainings did not reveal diﬀerences in
immune cell dynamics following light-exposure we measured expres-
sion of pro-inﬂammatory and anti-inﬂammatory microglia and macro-
phage markers (Gong et al., 2019) in whole retina lysates. Pro-
inﬂammatory phagocytes are characterized by the expression of pro-
inﬂammatory cytokines such as tumor necrosis factor-alpha (Tnfa) and
interleukin-6 (Il6) and interleukin-1b (Il1b), or interferon-responsive
genes, such as guanylate binding protein family member 6 (Gbp6)
(Gong et al., 2019). The expression of these markers increased similarly
in the retina of CTRL and Tspo-KO mice after light exposure with Tnfa,
Il6 and Il1b showing an early and strong upregulation at 12 h, with Il1b
slightly increased in Tspo-KO mice, followed by a decrease at 4 days
(Fig. 6E). Gbp6 was also increased at 12 h post-illumination and re-
mained elevated at least until 4 days after exposure. Among the anti-
inﬂammatory markers arginase-1 (Arg1) was the only gene that did not
show an obvious regulation after light-induced damage (Fig. 6F). In
contrast, chitinase-like 3 (Chil3, also known as Ym1) and mannose re-
ceptor, C type 1 (Mrc1) increased early (Chil3) or late (Mrc1) after light
Fig. 4. Retinal morphology and function in Tspo mice. A) Fundus images (upper panels) and optical coherence tomography (OCT) scans (lower panels) of CTRL and
Tspo-KO mice at 24 and 48 weeks of age. Asterisks indicate the ONL. B)Morphology of RPE (upper panels) and retina (lower panels) of CTRL and Tspo-KOmice at 24
and 48 weeks of age. C) Number of photoreceptor nuclei per area (see Material and Methods) at the indicated distances from the optic nerve in CTRL (blue lines) and
Tspo-KO (red lines) mice at 24 (circles) and 48 (triangles) weeks of age. D) Scotopic electroretinogram (ERG) recorded from dark-adapted CTRL (dotted blue lines)
and Tspo-KO (red lines) mice. Left: overlay of averaged traces of mice at 48 weeks of age. Right: a-wave (upper panel) and b-wave (lower panel) amplitudes of CTRL
(blue lines) and Tspo-KO (red lines) mice at 24 and 48 weeks of age. Amplitudes are blotted against the stimulus intensity. E) Photopic ERG recorded from light-
adapted CTRL (dotted blue lines) and Tspo-KO (red lines) mice. Left: overlay of averaged traces of mice at 48 weeks of age. Right: b-wave amplitudes as a function of
stimulus intensity of CTRL (dotted blue lines) and Tspo-KO (red lines) mice at 24 and 48 weeks of age. Scale bars: as indicated in the ﬁgure. Shown are means ± SD.
Statistics: (D, E): two-way ANOVA with Sidak's multiple comparison test. N≥ 3 (panels A–C). N≥ 4 (panels D, E). Abbreviations as in Fig. 1.
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exposure. Similar to the activation and migration of microglia and
macrophages, the expression pattern of activation markers after light
exposure was comparable for the two mouse strains. We also tested
expression levels of Caspase1 (Casp1) as this gene was implicated in
both apoptotic and inﬂammatory processes. Expression of Casp1 was
strongly upregulated late in both light-exposed Tspo-KO and control
mice (Fig. 6G). This suggests that TSPO does not regulate state or ac-
tivation dynamics of retinal mononuclear phagocytes in our
experimental setting.
4. Discussion
After almost four decades of studies, TSPO function remains dis-
puted. It is generally accepted that TSPO is expressed in reactive mi-
croglia and astrocytes at the site of brain injury (Anholt et al., 1985)
(reviewed in (Rupprecht et al., 2010)) and may thus be relevant for
Fig. 5. Retinal susceptibility to light-induced and inherited degeneration in the absence of Tspo. A) Number of photoreceptor nuclei per area (see Material and Methods) at
the indicated distances from the optic nerve head in CTRL (blue lines) and Tspo-KO (red lines) mice before (dark control, DC) and at 4 and 14 days after light damage
(LD). Shown are means ± SD. B - D) Representative morphologies of retinas from CTRL and Tspo-KO mice before (B), or at 4 (C) and 14 days (D) post-illumination.
Yellow arrowheads point to phagocytic cells localized in the subretinal space. E) Number of photoreceptor nuclei per area at the indicated distances from the optic
nerve head in rd10 (blue lines) and Tspo-KO;rd10 double mutant (red lines) mice at 8 weeks of age. F) Representative morphologies of retinas from rd10 and Tspo-
KO;rd10 mice at 8 weeks of age. Scale bar: 50 μm. N=3. Abbreviations as in Fig. 1.
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Fig. 6. Microglia and macrophage dynamics after light-induced degeneration in CTRL and Tspo-KO mice. A, B) Immunoﬂuorescence staining with anti-IBA-1 (white) (A)
and anti-TSPO (orange) antibodies (B) on retinal cryosections of dark controls (DC) and at 4 and 14 days following light damage (LD) as indicated. Blue: DAPI. C)
Immunoﬂuorescence staining with anti-IBA-1 antibodies (white) of retinal ﬂat mounts prepared from dark controls (DC) or at 4 days after light exposure (LD 4 d).
Shown are overview images and images of higher magniﬁcations with the focus plane either on the GCL (DC mice) or the ONL (LD 4 d mice). Note that rectangles in
overview images indicate the position of the images with higher magniﬁcation but are not to scale D) Quantiﬁcation of IBA1-positive cells in areas of
450 μm2×320 μm2. Shown are individual values of all 4 areas per retina, as well as means ± SD. Top: microglia in the GCL of DC mice. Bottom: microglia in the
ONL of LD mice at 4 d post-exposure. N=3. E) Gene expression levels of the pro-inﬂammatory microglia and macrophage markers Tnfa, Il6, Gbp6 and Il1b before and
at 12 h and 4 d after light exposure in CTRL (blue) and Tspo-KO (red) mice. Shown are individual values and means ± SD of N=3. F) Gene expression levels of the
anti-inﬂammatory microglia and macrophage markers Arg1, Chil3 andMrc1 before and at 12 h and 4 d after light exposure in CTRL (blue) and Tspo-KO (red) mice. G)
Gene expression levels of Casp1 as a marker for apoptotic (cell death) and inﬂammatory processes. Shown are individual values and means ± SD of N=3. Scale
bars: as indicated.
K. Klee, et al. Experimental Eye Research 188 (2019) 107816
9
neural pathologies. Indeed, TSPO ligands showed neuroprotective
outcomes in mouse models of neurodegeneration (Girard et al., 2008;
Gong et al., 2019; Leva et al., 2017; Scholz et al., 2015) and demon-
strated anxiolytic eﬀects in humans (Rupprecht et al., 2010). In addi-
tion, more than 40 clinical trials (https://clinicaltrials.gov/ct2/home)
tested eﬃcacy of TSPO radioligands for PET imaging of patients suf-
fering from a neurodegenerative disease or traumatic brain injury. To
approach TSPO function, it is thus crucial to investigate its expression
in neuronal tissues in health and disease.
We showed earlier that TSPO is not only expressed in the retina but
also in the RPE of the adult mouse (Scholz et al., 2015; Storti et al.,
2019). Here, we established that TSPO has a similar expression proﬁle
in human donor eyes, with strong expression of TSPO in both retina and
RPE. Furthermore, we show that Tspo is upregulated in the mouse re-
tina but not in the RPE during retinal degeneration (Fig. 2), in-
dependent of whether the degeneration is caused by a mutation af-
fecting primarily the neural retina (rd10 mice) or the RPE
(RPEΔAbca1;Abcg1 mice). Recent in vitro studies of the TSPO promoter
demonstrated that BV-2 cells (microglia) and ARPE-19 (RPE) cells use
diﬀerent promoter elements for regulating expression providing further
evidence for a cell speciﬁc and diﬀerential regulation of TSPO in im-
mune and RPE cells (Rashid et al., 2018).
The increase of Tspo expression in the retina of rd10 mice coincided
with an increase in microglia density in the ONL (Zhao et al., 2015) and
elevated expression of inﬂammatory markers such as interleukin-1beta
and caspase-1 (Samardzija et al., 2012). Thus, increased Tspo expres-
sion in the neural retina likely reﬂects ongoing inﬂammatory reactions
and microglia activation. Surprisingly however, expression of Tspo re-
mained elevated at least until 1 year of age, a time when microglia
density in the outer retina has long returned to basal levels (Zhao et al.,
2015). During this late phase of degeneration, Müller glia cells may
express TSPO as immunoﬂuorescence analysis of 6-month-old rd10
mice revealed a TSPO staining pattern characteristic for Müller cells in
the inner retina (supplementary Figure 1). Müller cell-speciﬁc expres-
sion of TSPO has already been shown in a mouse model for retinal
ischemia (Mages et al., 2019), and a cross-talk between microglia and
Müller cells has been suggested during degenerative processes (Roche
et al., 2018). Such a cross-talk may include diazepam-binding inhibitor
(DBI) that is produced in Müller cells and interacts with TSPO in mi-
croglia leading to reduced production of TNFa, lower levels of reactive
oxygen species and diminished microglia activity (Wang et al., 2014).
The signiﬁcance of a Müller cell speciﬁc expression of TSPO in the
degenerated retina (e.g. for gliosis) has still to be determined, especially
since absence of TSPO from the rd10 retina did not inﬂuence the de-
generative process (Fig. 5E and F).
Like activated microglia, RPE cells are very active phagocytes and
participate in the removal of debris from the subretinal space during
retinal degeneration. In contrast to microglia, however, RPE cells did
not upregulate Tspo expression during degenerative processes even
when the primary defect was in the RPE (RPEΔAbca1;Abcg1; BEST1-Cre
mice, Fig. 2B). Thus, TSPO may not be involved in the phagocytic
function of the RPE or activated microglia, a conclusion supported by
the absence of an accumulation of cellular debris from the degenerating
outer retina in light-damaged and rd10 mice with or without TSPO
(Fig. 5). Taken together our results suggest that Tspo expression is
regulated in the neural retina but constitutive in the RPE and may not
aﬀect phagocytic activities.
In accordance with the idea of TSPO being a stress-related protein,
Tspo-KO mice did not develop any ocular phenotype and demonstrated
normal retinal morphology and function up to 48 weeks of age (Fig. 4).
A non-essential function of TSPO for normal mouse physiology is also
supported by reports from several groups that independently generated
systemic Tspo-KO mouse lines (Banati et al., 2014; Barron et al., 2018;
Tu et al., 2014; Wang et al., 2016). None of them showed an obvious
phenotype, suggesting that TSPO is not necessary for mouse re-
production, development and aging. However, the debate about a
potential relevance of TSPO for steroidogenesis has been refuelled by
recent studies that reported diﬀerential regulation of steroids in adult
Tspo-KOmice (Barron et al., 2018), as well as in mutant rats and human
patients carrying TSPO polymorphisms (Owen et al., 2017) (reviewed
in (Costa et al., 2018)).
Lack of a retinal phenotype even under stress conditions may also
argue against an involvement of TSPO in the mitochondrial perme-
ability transition (MPT) pore, a connection that has been proposed
mainly on the basis of eﬀects observed after application of TSPO ligands
(Azarashvili et al., 2015). But since such ligands may inﬂuence cell
physiology also independently of TSPO (Gonzalez-Polo et al., 2005;
Hans et al., 2005), a connection of TSPO with MPT is still con-
troversially discussed (Bernardi and Di Lisa, 2015; Chelli et al., 2001;
Zoratti et al., 2005). Similarly, the proposed connection of TSPO to
mitochondria quality control and regulation of mitophagy (Gatliﬀ et al.,
2014, 2017), which also has been implicated in retinal degeneration
(Brown et al., 2018; Hyttinen et al., 2018; Lefevere et al., 2017), may
not be strengthen by our data since absence of TSPO did not alter
progression of degeneration in our models (Fig. 5). The lack of a clearly
deﬁned TSPO function and/or phenotype in knockout studies caused
several groups to propose the existence of mechanisms that compensate
for the absence of TSPO, but the potential nature of such mechanisms
has not been identiﬁed or discussed in detail (Papadopoulos et al.,
2018).
TSPO generates strong interest because of its proven regulation in
activated microglia and in astrocytes in the retina and CNS (reviewed in
(Bennett et al., 2016)) (Cosenza-Nashat et al., 2009; Guilarte, 2019;
Karlstetter et al., 2014; Scholz et al., 2015). Quiescent microglia are
ramiﬁed and survey the neuronal environment with their processes. In
presence of damage they become activated, change their morphology to
an amoeboid shape, express TSPO, migrate to the site of damage and
initiate phagocytosis of cellular debris. Short-term and controlled mi-
croglia activation is beneﬁcial for the damaged tissue. However, long-
term unrestrained activation can be detrimental, as microglia might
phagocyte also healthy and functional cells (reviewed in (Langmann,
2007)). Thus, a tightly controlled regulation of microglia activity seems
pivotal to preserve tissue from further damage. This might be achieved
by the application of TSPO ligands that were reported to have micro-
glia-modulatory activity and neuroprotective properties (Gong et al.,
2019; Karlstetter et al., 2014; Leva et al., 2017; Scholz et al., 2015). For
instance, mice of a model for Parkinson's disease (PD) showed better
retention of dopaminergic neurons, improved motor activity and a shift
of microglia/macrophages from the pro-inﬂammatory to the anti-in-
ﬂammatory state when injected with the TSPO ligand XBD173 (Gong
et al., 2019). XBD173 was also shown to modulate the inﬂammatory
behaviour of immune cells in a mouse model for multiple sclerosis (EAE
model) leading to improved motor function and preserved myelin basic
protein distribution in the CNS (Leva et al., 2017), and to attenuate the
response of microglia and Müller cells in a model of retinal ischemia
(Mages et al., 2019). Scholz et al. (2015), reported protection against
light-induced retinal degeneration by systemic application of XBD173
and attributed the protection to dampened microglia activation. Indeed,
in vitro assays from the same group showed that XBD173 treatment of
murine and human microglia decreased their proliferation and ex-
pression of pro-inﬂammatory cytokines as well as production nitric
oxygen radicals (Karlstetter et al., 2014). Similar results were obtained
with mouse models for sciatic nerve injury (Girard et al., 2008) where
mice treated with etifoxine, another TSPO ligand, exhibited better ax-
onal regeneration, better motor recovery and reduced macrophage in-
ﬁltration. However, these authors proposed that reduced microglia/
macrophage activation might be a bystander eﬀect whereas axonal
regrowth was attributed to TSPO-dependent mechanisms intrinsic to
neurons themselves. Whether TSPO ligands mediate their protective
eﬀects in vivo by a direct modulation of microglia activity or by other
means is thus still a matter of debate that is further complicated by
anxiolytic eﬀects of TSPO ligands (Rupprecht et al., 2009). Such eﬀects
K. Klee, et al. Experimental Eye Research 188 (2019) 107816
10
may inﬂuence the outcome of tests designed to investigate neuronal
function by behavioural assays. We also need to consider that dam-
pened microglia activation observed in several animal models treated
with TSPO-ligands could be the consequence of an indirect eﬀect.
TSPO-ligands might protect neurons by unknown mechanisms leading
to reduced tissue damage and, as a consequence, indirectly to reduced
microglia activity.
Considering that various CNS pathologies improved after the ap-
plication of TSPO ligands (Gong et al., 2019; Leva et al., 2017; Scholz
et al., 2015) we expected stronger retinal degeneration and reduced
microglia activation in our mouse models when they lacked TSPO.
Since this was not the case, we conclude that absence of TSPO does not
aﬀect microglia activation or neuronal preservation by itself, but that
the interaction of TSPO with a ligand might be fundamental to achieve
neuroprotection.
With this work, we demonstrated that TSPO is expressed in the
neural retina and RPE in mouse and human eyes, but that it is regulated
only in the neural retina upon tissue damage. Lack of TSPO did not lead
to a retinal phenotype in physiological conditions, did not inﬂuence the
susceptibility of the retina to degeneration and did not aﬀect microglia
and macrophage dynamics in the degenerating retina. We hypothesize
that TSPO may not be capable of modulating the course of retinal de-
generation by itself but may need interacting partners and/or addi-
tional factors to initiate a mechanism that leads to tissue preservation.
The identiﬁcation of these mechanisms may not only help to design
neuroprotective strategies but may also shed light onto TSPO function.
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